Watch RCUS. Know when insiders buy.
One email the day a filing lands. Free.
Work order
42
WATCH · insiders 46, shorts 37
Insiders, 90 days
−$85K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.8BP/E —DIV YIELD —FCF YIELD -12.58%REV TTM $117M −55.3%NET INCOME −$460MNET CASH $49M52W 11.32 – 31.57SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $41M | −74.4% | — | −$96M | −$91M | — | -0.72 | −$119M | $0 | −$119M | Aug 5 |
| Q1 2026 · Mar 31 | $17M | −39.3% | — | −$134M | −$128M | — | -1.02 | −$138M | $0 | −$138M | Aug 5 |
| Q4 2025 · Dec 31derived | $33M | +26.9% | — | −$114M | −$106M | — | -0.90 | −$120M | $1M | −$121M | Feb 25 |
| Q3 2025 · Sep 30 | $26M | −45.8% | — | −$142M | −$135M | — | -1.27 | −$97M | $0 | −$97M | Oct 28 |
| Q2 2025 · Jun 30 | $160M | +310.3% | — | −$8M | $0 | — | 0.00 | −$133M | $0 | −$133M | Aug 5 |
| Q1 2025 · Mar 31 | $28M | −80.7% | — | −$122M | −$112M | — | -1.14 | −$132M | $1M | −$133M | Aug 5 |
| Q4 2024 · Dec 31derived | $26M | −16.1% | — | −$103M | −$94M | — | -1.03 | −$100M | $1M | −$101M | Feb 25 |
| Q3 2024 · Sep 30 | $48M | +50.0% | — | −$105M | −$92M | — | -1.00 | $26M | $1M | $25M | Oct 28 |
| Q2 2024 · Jun 30 | $39M | — | — | −$106M | −$93M | — | -1.02 | −$94M | $0 | −$94M | Oct 28 |
| Q1 2024 · Mar 31 | $145M | — | — | −$16M | −$4M | — | -0.05 | −$2M | $4M | −$6M | Oct 28 |
| Q4 2023 · Dec 31derived | $31M | — | — | −$91M | −$81M | — | -1.08 | −$88M | $6M | −$94M | Feb 25 |
| Q3 2023 · Sep 30 | $32M | — | — | −$80M | −$71M | — | -0.94 | −$63M | $10M | −$73M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $247M | — | −$386M | −$353M | -142.9% | -3.29 | −$482M | $2M | −$484M | — | — |
| FY2024 · to Dec 31 | $258M | — | −$330M | −$283M | -109.7% | -3.14 | −$170M | $6M | −$176M | — | — |
| FY2023 · to Dec 31 | $117M | — | −$340M | −$307M | -262.4% | -4.15 | −$306M | $24M | −$330M | — | — |
| FY2022 · to Dec 31 | $112M | — | −$280M | −$267M | -238.4% | -3.71 | $438M | $6M | $432M | — | — |
| FY2021 · to Dec 31 | $383M | — | $54M | $53M | 13.8% | 0.71 | −$256M | $26M | −$282M | — | — |
| FY2020 · to Dec 31 | $78M | — | −$124M | −$123M | -157.7% | -2.24 | $111M | $3M | $108M | — | — |
Every number comes from Arcus Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.